BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Lv XY, Ding HG, Zheng JF, Fan CL, Li L. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World J Gastroenterol 2020; 26(2): 199-218 [PMID: 31988585 DOI: 10.3748/wjg.v26.i2.199]
URL: https://www.wjgnet.com/1007-9327/full/v26/i2/199.htm
Number Citing Articles
1
Bradley Reuter, Jasmohan S. Bajaj. MicrobiomeClinics in Liver Disease 2020; 24(3): 493 doi: 10.1016/j.cld.2020.04.006
2
Thomas H. Tranah, Victoria T. Kronsten, Debbie L. Shawcross. Implications and Management of Cirrhosis‐Associated Immune Dysfunction Before and After Liver TransplantationLiver Transplantation 2022; 28(4): 700 doi: 10.1002/lt.26353
3
Xiao Yu, Ye Jin, Wangxiao Zhou, Tingting Xiao, Zhongwen Wu, Junwei Su, Hainv Gao, Ping Shen, Beiwen Zheng, Qixia Luo, Lanjuan Li, Yonghong Xiao. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the ResistomeFrontiers in Cellular and Infection Microbiology 2022; 11 doi: 10.3389/fcimb.2021.761192
4
Igor G. Bakulin, Inna A. Oganezova, Maria I. Skalinskaya, Ekaterina V. Skazyvaeva. Liver cirrosis and complication risk managementTerapevticheskii arkhiv 2021; 93(8): 963 doi: 10.26442/00403660.2021.08.200917
5
Charles E. Gallaher, Debbie L. Shawcross. Management of Multidrug-Resistant Infections in CirrhosisSeminars in Liver Disease 2022; 42(02): 173 doi: 10.1055/a-1765-0056
6
Jasmohan S Bajaj, Amirhossein Shamsaddini, Chathur Acharya, Andrew Fagan, Masoumeh Sikaroodi, Edith Gavis, Sara McGeorge, Alexander Khoruts, Michael Fuchs, Richard K Sterling, Hannah Lee, Patrick M Gillevet. Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosisGut Microbes 2021; 13(1) doi: 10.1080/19490976.2021.1993584
7
Giacomo Zaccherini, Manuel Tufoni, Mauro Bernardi, Paolo Caraceni. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying AgentsJournal of Clinical Medicine 2021; 10(19): 4590 doi: 10.3390/jcm10194590
8
Paolo Caraceni, Victor Vargas, Elsa Solà, Carlo Alessandria, Koos Wit, Jonel Trebicka, Paolo Angeli, Rajeshwar P. Mookerjee, François Durand, Elisa Pose, Aleksander Krag, Jasmohan S. Bajaj, Ulrich Beuers, Pere Ginès, Adrià Juanola, Laura Napoleone, Marta Carol, Emma Avitabile, Ann Ma Thu, Marta Cervera, Martina Pérez, Ana Belén Rubio‐Garcia, Alicia Ardiaca, Adriana Vives, Judit Pich, Núria Fabrellas, Giacomo Zaccherini, Maria Teresa Chiappa, César Jiménez, Ester Palacio, Daniela Campion, Tommaso Lanzillotti, Salvatore Piano, Gea Nicolao, Frank Uschner, Sabine Graf_Dirmeier, Claire Francoz, Olivier Roux, Vanessa Esnault, Jeltje Helder, Marites Aban, Konstantin Kazankov, Marko Korenjak, Patrick Kamath, Juan G. Abraldes, Hugh Watson. The Use of Rifaximin in Patients With CirrhosisHepatology 2021; 74(3): 1660 doi: 10.1002/hep.31708
9
Paolo Caraceni, Juan G. Abraldes, Pere Ginès, Phil N. Newsome, Shiv K. Sarin. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discoveryJournal of Hepatology 2021; 75: S118 doi: 10.1016/j.jhep.2021.01.024
10
Rui-fang Zhu, Yu-lu Gao, Sue-Ho Robert, Jin-ping Gao, Shi-gui Yang, Chang-tai Zhu. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19)Journal of Translational Medicine 2020; 18(1) doi: 10.1186/s12967-020-02442-5